Vivet Therapeutics Chief Executive Officer, Jean-Philippe Combal will be attending the 7th Annual Gene Therapy for Rare Disorders Summit, taking place from 26-29 March in Boston, MA!
The Summit brings together key players from leading biopharma companies that are advancing the field of gene therapies and is the leading meeting for collectively advancing rare hashtaggenetherapy programs into and through the clinic for the benefit of patients living with hashtagrarediseases.
Follow hashtagVivet to learn more about its diversified gene therapy platform which uses recombinant adeno-associated virus (hashtagrAAVs) as vectors for the treatment of rare inherited liver metabolic disorders including hashtagWilsonsDisease, hashtagCTX, hashtagProgressiveFamilialIntrahepaticCholestasis (hashtagPFIC) and hashtagcitrullinemiatypeI (hashtagCTLN1).
Learn about hashtagVivet‘s diversified gene therapy pipeline and patented technologies using the link in the first comment below.
